606 results match your criteria Botulinum Toxin in Pain Management


Nonaesthetic Applications for Botulinum Toxin in Plastic Surgery.

Plast Reconstr Surg 2020 Jul;146(1):157-170

New York, N.Y. From the Division of Plastic and Reconstructive Surgery, Department of Surgery, Mount Sinai Hospital.

Background: Since their introduction to clinical medicine in 1989, botulinum toxin injections have been used for many indications. First used for nonsurgical management of strabismus, botulinum toxin injections are now widely used in plastic and reconstructive surgery for aesthetic indications; however, nonaesthetic indications of botulinum toxin have grown tremendously over the past two decades and span numerous specialties, including urology, dermatology, ophthalmology, otolaryngology, gynecology, plastic surgery, general surgery, and neurology. The present review aims to highlight nonaesthetic indications of botulinum toxin that are most relevant to the plastic surgeon with an emphasis on evidence-based practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PRS.0000000000006908DOI Listing

The Use of Botulinum Toxin in the Management of Headache Disorders.

Handb Exp Pharmacol 2020 Jun 20. Epub 2020 Jun 20.

Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA.

Tremendous progress has been made in the past decades for the treatment of headache disorders. Chronic migraine is the most disabling type of headache and requires the use of acute and preventive medications, many of which are associated with adverse events that limit patient adherence. Botulinum toxin (BoNT) serotype A, a neurotoxin derived from certain strains of Clostridium, disrupts neuropeptide secretion and receptor translocation related to trigeminal nociception, thereby preventing pain sensitization through peripheral and possibly central mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/164_2020_365DOI Listing

Peroral endoscopic myotomy for management of gastrointestinal motility disorder.

World J Clin Cases 2020 Jun;8(11):2116-2126

Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.

Achalasia is a type of esophageal motility disorder, consisting of relaxation dysfunction of the lower esophagus and disturbed esophageal peristalsis. Related clinical symptoms include dysphagia, regurgitation, chest pain, and weight loss. Traditional treatment options include endoscopic botulinum toxin injection, endoscopic pneumatic dilation, and laparoscopic Heller's myotomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12998/wjcc.v8.i11.2116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281049PMC

A Comprehensive Review of the Diagnosis, Treatment, and Management of Postmastectomy Pain Syndrome.

Curr Pain Headache Rep 2020 Jun 11;24(8):41. Epub 2020 Jun 11.

Department of Anesthesiology and Pharmacology, Toxicology, and Neurosciences, Louisiana State University School of Medicine, Shreveport, LA, USA.

Purpose Of Review: Postmastectomy pain syndrome (PMPS) remains poorly defined, although it is applied to chronic neuropathic pain following surgical procedures of the breast, including mastectomy and lumpectomy in breast-conserving surgery. It is characterized by persistent pain affecting the anterior thorax, axilla, and/or medial upper arm following mastectomy or lumpectomy. Though the onset of pain is most likely to occur after surgery, there may also be a new onset of symptoms following adjuvant therapy, including chemotherapy or radiation therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11916-020-00876-6DOI Listing

Utilization of Botulinum Toxin for Musculoskeletal Disorders.

Curr Sports Med Rep 2020 Jun;19(6):217-222

Uniformed Services University of the Health Sciences, Bethesda, MD.

Rehabilitation from musculoskeletal injuries is challenging with multiple intrinsic and extrinsic factors influencing athletes, conditions, and length of recovery. Multidisciplinary treatment strategies aim to address pathophysiology, mechanical, and psychosocial factors of injuries. An essential element in the recovery from musculoskeletal injuries is pain control and the return of physiologic function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1249/JSR.0000000000000720DOI Listing

A prospective real-world analysis of erenumab in refractory chronic migraine.

J Headache Pain 2020 Jun 1;21(1):61. Epub 2020 Jun 1.

The Headache Centre, Pain Management and Neuromodulation Centre, Guy's and St Thomas NHS Foundation Trust, London, UK.

Background: Clinical trials have shown the safety and clinical superiority of erenumab compared to placebo in chronic migraine (CM). The aim of this analysis is to evaluate the effectiveness and tolerability of erenumab in a real-world setting in patients with refractory CM.

Methods: This is a prospective single centre real-world audit conducted in patients with CM with and without medication overuse, refractory to established preventive medications, who received monthly erenumab for 6 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s10194-020-01127-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268737PMC

Patient Perspectives on the Therapeutic Profile of Botulinum Neurotoxin Type A in Spasticity.

Front Neurol 2020 7;11:388. Epub 2020 May 7.

MossRehab and Albert Einstein Medical Center, Elkins Park, PA, United States.

Botulinum toxin-A (BoNT-A) injections are first-line treatment for adult spasticity. Prior patient surveys have reported that BoNT-A treatment improves quality of life but that symptoms usually recur before the next injection. We aimed to explore, in-depth, patient perceptions of the impact of spasticity and the waning of BoNT-A therapeutic effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2020.00388DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233119PMC

The role of intrasphincteric botulinum toxin injection in the management of functional biliary pain: a systematic review and meta-analysis.

Eur J Gastroenterol Hepatol 2020 May 22. Epub 2020 May 22.

Department of Gastroenterology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK.

Background: The management of postcholecystectomy functional biliary pain or Type III sphincter of Oddi dysfunction is challenging. The Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction study has demonstrated the lack of efficacy of endoscopic sphincterotomy in the management of Type III sphincter of Oddi dysfunction.

Objective And Methods: Botulinum toxin injection to the sphincter of Oddi has been reported as being effective in uncontrolled studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0000000000001773DOI Listing

Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience.

Rheumatol Int 2020 May 23. Epub 2020 May 23.

Department of Plastic and Reconstructive Surgery, Saint Helens and Knowsley NHS Trust, Whiston Hospital, Warrington Road, Prescot, L35 5DR, United Kingdom.

Raynaud's phenomenon is a vasospastic condition affecting hands and feet which may lead to rest pain, ischemic ulcers and gangrene. Botulinum toxin A has been shown to improve peripheral circulation and relieve vasospastic symptoms. Our aim was to assess our treatment outcomes following Botulinum toxin A injections in patients with Raynaud's phenomenon and to explore the importance of toxin concentration and injection sites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00296-020-04606-4DOI Listing

An update on the pharmacological management of pain in patients with multiple sclerosis.

Expert Opin Pharmacother 2020 Apr 28:1-15. Epub 2020 Apr 28.

Department "GF Ingrassia", Section of Neurosciences, University of Catania, Catania, Italy.

: The prevalence of pain in Multiple Sclerosis (MS) is estimated to be between 29-86% depending on various stages of the disease. According to a recent mechanism-based classification, MS pain syndromes include ongoing extremity pain, trigeminal neuralgia, and Lhermitte's phenomenon, painful tonic spasms and spasticity pain, pain associated with optic neuritis, musculoskeletal pain, migraine, and treatment-induced pain.: Pharmacological approaches for MS pain include anticonvulsants, antidepressants, botulinum toxin, cannabinoids, muscle relaxants, opioid analgesics, and intrathecally administered baclofen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2020.1757649DOI Listing

Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study.

Neurol Sci 2020 Apr 12. Epub 2020 Apr 12.

Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Sciences and Odontostomatology, "Federico II" University of Naples, Via Sergio Pansini 5, edificio 17 piano terra, 80131, Naples, Italy.

Background: Botulinum toxin (BT) is an effective and safe treatment for spasticity, with limited evidence in multiple sclerosis (MS). We aim to describe the use of BT for the management of MS spasticity in the clinical practice, its combination with other anti-spastic treatments in MS and possible MS clinical correlates.

Methods: This is a multicentre cross-sectional observational study including 386 MS patients, receiving BT for spasticity in 19 Italian centres (age 53. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10072-020-04392-8DOI Listing

Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations.

Rev Neurol (Paris) 2020 May 7;176(5):325-352. Epub 2020 Apr 7.

INSERM U987, CETD, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt, France; Université Versailles - Saint-Quentin-en-Yvelines, Versailles, France.

Neuropathic pain remains a significant unmet medical need. Several recommendations have recently been proposed concerning pharmacotherapy, neurostimulation techniques and interventional management, but no comprehensive guideline encompassing all these treatments has yet been issued. We performed a systematic review of pharmacotherapy, neurostimulation, surgery, psychotherapies and other types of therapy for peripheral or central neuropathic pain, based on studies published in peer-reviewed journals before January 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurol.2020.01.361DOI Listing

Botulinum Toxin Therapy for Managing Sleep Bruxism: A Randomized and Placebo-Controlled Trial.

Toxins (Basel) 2020 Mar 9;12(3). Epub 2020 Mar 9.

Department of Orofacial Pain and Oral Medicine, College of Dentistry, Yonsei University, Seoul 03722, Korea.

The purpose of this study is to evaluate the effects of botulinum toxin type A (BoNT-A) for managing sleep bruxism (SB) in a randomized, placebo-controlled trial. Thirty SB subjects were randomly assigned into two groups evenly. The placebo group received saline injections into each masseter muscle, and the treatment group received BoNT-A injections into each masseter muscle. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/toxins12030168DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150956PMC

Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders-From Bench to Bedside.

Toxins (Basel) 2020 Mar 9;12(3). Epub 2020 Mar 9.

Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970, Taiwan.

Bladder oversensitivity arises from several different conditions involving the bladder, bladder outlet, systemic or central nervous system diseases. Increase of the bladder sensation results from activation of the sensory receptors in the urothelial cells or suburothelial tissues. Medical treatment targeting the overactive bladder (OAB) or interstitial cystitis (IC) might relieve oversensitive bladder symptoms (frequency, urgency and pain) in a portion of patients, but a certain percentage of patients still need active management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/toxins12030166DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150911PMC
March 2020
2.480 Impact Factor

Needling therapies in the management of myofascial pain of the masticatory muscles: A network meta-analysis of randomised clinical trials.

J Oral Rehabil 2020 Jul 22;47(7):910-922. Epub 2020 Apr 22.

Division of Oral Diagnostics and Rehabilitation, Department of Dental Medicine, Karolinska Institutet, Huddinge, Sweden.

Objective: A network meta-analysis (NMA) of randomised clinical trials (RCTs) was performed aiming to compare the treatment outcome of dry needling, acupuncture or wet needling using different substances in managing myofascial pain of the masticatory muscles (TMD-M).

Method: An electronic search was undertaken to identify RCTs published until September 2019, comparing dry needling, acupuncture or wet needling using local anaesthesia (LA), botulinum toxin-A (BTX-A), granisetron, platelet-rich plasma (PRP) or passive placebo versus real active placebo in patients with TMD-M. RCTs meeting the inclusion criteria were stratified according to the follow-up time: immediate post-treatment to 3 weeks, and 1 to 6 months post-treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/joor.12960DOI Listing
July 2020
1.934 Impact Factor

Botulinum toxin in the management of temporomandibular disorders: a systematic review.

Br J Oral Maxillofac Surg 2020 Jun 3;58(5):508-519. Epub 2020 Mar 3.

Dept. of Oral & Maxillofacial Surgery, Gold Coast University Hospital, 1 Hospital Boulevard, Southport, QLD, 4215, Australia.

The aim of this review was to critically investigate and assess the evidence relating to the use and efficacy of botulinum toxin (BTX) in the management of temporomandibular joint disorders (TMD) and masticatory myofascial pain. A comprehensive search was conducted of PubMed, Scopus, Embase, and Cochrane CENTRAL, to find relevant studies from the last 30 years up to the end of July 2018. Seven were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bjoms.2020.02.007DOI Listing

The Use of Botulinum Toxin in Pain Management: Basic Science and Clinical Applications.

Plast Reconstr Surg 2020 03;145(3):629e-636e

Columbus, Ohio From the Department of Plastic and Reconstructive Surgery, Ohio State University Wexner Medical Center.

Pain is an unpleasant experience resulting from either tissue damage or insults to the somatosensory system. Approaches to pain management evolve as we better understand both pain pathways and the tools available to interrupt these. The interest surrounding botulinum neurotoxin as a chemodenervating agent has expanded to include its potential applications in painful pathologies, both within and beyond the confines of plastic surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PRS.0000000000006559DOI Listing

Injection location does not impact botulinum toxin A efficacy in interstitial cystitis/bladder pain syndrome patients.

Can J Urol 2020 Feb;27(1):10125-10129

Department of Urology/Female Pelvic Health, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA.

Introduction: Botulinum toxin A (BTX-A) is currently used as a fourth-line therapeutic option for interstitial cystitis/bladder pain syndrome (IC/BPS) management. The purpose of this study was to determine if BTX-A injection can mitigate pain and if injection location (i.e. Read More

View Article

Download full-text PDF

Source
February 2020

A questionnaire survey on the efficacy of various treatments for dyskinetic cerebral palsy due to preterm bilirubin encephalopathy.

Brain Dev 2020 Apr 13;42(4):322-328. Epub 2020 Feb 13.

Department of Pediatric Neurology, Bobath Memorial Hospital, Osaka, Japan.

Objectives: Preterm children with severe dyskinetic cerebral palsy due to bilirubin encephalopathy often suffer from marked generalised hypertonus as they age. We performed a questionnaire survey to investigate patient-reported outcomes of treatments for improving their activities of daily life.

Methods: A mail questionnaire was administered to the caregivers of 67 children with preterm bilirubin encephalopathy aged >4 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.braindev.2020.01.006DOI Listing

Current Status of Pain Management in Parkinson's Disease.

Can J Neurol Sci 2020 May;47(3):336-343

Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.

Background: Pain is a non-motor symptom in Parkinson's disease (PD) which commonly goes underreported. Adequate treatment for pain in PD remains challenging, and to date, no clear guidelines for management are available.

Methods: With the goal of understanding and organizing the current status of pain management in PD, we conducted a review of pharmacological and non-pharmacological treatments for pain in patients with PD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/cjn.2020.13DOI Listing

Editorial Comment.

Authors:
Ryan P Smith

J Urol 2020 04 9;203(4):772. Epub 2020 Jan 9.

Reproductive Medicine and Surgery, Department of Urology, University of Virginia, Charlottesville, Virginia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000658.02DOI Listing

Editorial Comment.

Authors:
R Matthew Coward

J Urol 2020 04 9;203(4):772. Epub 2020 Jan 9.

Urology Department, University of North Carolina, Chapel Hill, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000658.01DOI Listing

Complications of botulinum toxin and fillers: A narrative review.

J Cosmet Dermatol 2020 Mar 30;19(3):570-573. Epub 2019 Dec 30.

Department of Dermatology, University Medical Center Mainz, Mainz, Germany.

Background: Cosmetic surgery and esthetic procedures have become a billion dollar industry owing to the ever-growing demand of the population to stay young. The injectable treatments including fillers and botulinum toxin have become highly popular because of their quick, predictable and lasting results in the management of facial wrinkles and rejuvenation. Although these treatment modalities are relatively safe, they are associated with certain side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jocd.13266DOI Listing

Clinical evaluation of botulinum toxin A in the management of temporomandibular myofascial pain.

Br J Oral Maxillofac Surg 2020 Feb 15;58(2):190-193. Epub 2019 Dec 15.

Aintree University NHS Foundation Trust, Lower Lane, Liverpool, L9 7AL. Electronic address:

We did a clinical service evaluation of patient-reported outcomes for pain and change in interincisal distance in patients treated with botulinum toxin A (BTX-A) for temporomandibular myofascial pain at nurse-led clinics. We retrospectively reviewed the clinical records of 100 patients and the prescribing patterns of two OMFS consultants. The mean starting pain score of 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bjoms.2019.11.010DOI Listing
February 2020

Use of botulinum toxin to heal atypical pressure ulcers in the palm.

Med J Aust 2020 02 13;212(2):65-66.e1. Epub 2019 Dec 13.

Queen Elizabeth Hospital, Adelaide, SA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5694/mja2.50452DOI Listing
February 2020

How can we improve the diagnosis and management of bladder pain syndrome? Part 2:ICI-RS 2018.

Neurourol Urodyn 2019 12;38 Suppl 5:S71-S81

Department of Urologic Surgery, Vanderbilt University, Nashville, Tennessee.

Background: This paper summarises the discussion in a think tank at the International Consultation on Incontinence-Research Society (ICI-RS) 2018 about the treatment of bladder pain syndrome.

Aims: To review the treatments of bladder pain syndrome from behavioural treatments to surgical interventions.

Materials And Methods: Review the literature in the light of the think tank discussions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/nau.24245DOI Listing
December 2019

Real-World Safety And Effectiveness Of OnabotulinumtoxinA Treatment Of Crow's Feet Lines And Glabellar Lines: Results Of A Korean Postmarketing Surveillance Study.

Clin Cosmet Investig Dermatol 2019 19;12:851-856. Epub 2019 Nov 19.

Global Patient Safety and Epidemiology, Allergan Holdings Ltd, Marlow, Buckinghamshire, UK.

Purpose: OnabotulinumtoxinA is approved in the Republic of Korea for the treatment of moderate-to-severe crow's feet lines (CFL) and glabellar lines (GL), separately or in combination. We assessed safety and effectiveness of onabotulinumtoxinA in real-world clinical practice.

Patient And Methods: This 4-year postmarketing surveillance study was conducted in the Republic of Korea in subjects with moderate-to-severe CFL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CCID.S227493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875486PMC
November 2019

The Effect of Botulinum Toxin Injection into the Common Extensor Tendon in Patients with Chronic Lateral Epicondylitis: A Randomized Trial.

Pain Med 2019 Dec 5. Epub 2019 Dec 5.

Department of Rehabilitation Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea.

Background: Botulinum toxin (BTX) is widely used for pain control in various musculoskeletal disorders.

Objectives: We evaluated the analgesic effect of botulinum toxin type A (BTX-A) in chronic lateral epicondylitis and compared the effect between 10 and 50 IU of BTX-A.

Methods: Sixty subjects with chronic lateral epicondylitis were included and underwent a BTX-A injection in the common extensor tendon. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/pm/pnz323DOI Listing
December 2019

Caregiver burden and health-related quality of life in idiopathic dystonia patients under botulinum toxin treatment: a cross-sectional study.

J Neural Transm (Vienna) 2020 01 4;127(1):61-70. Epub 2019 Dec 4.

Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

Dystonia is a chronic movement disorder that is associated with a reduction in health-related quality of life (HR-QoL) and restriction of activities of daily living. Botulinum neurotoxin (BT) improves disease-specific HR-QoL by reducing abnormal movements, postures, and pain. We examined the burden of the corresponding primary caregiver as a potential important factor for disease management and HR-QoL of dystonia patients under treatment with BT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00702-019-02109-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942568PMC
January 2020

Wearing Off Effect of OnabotulinumtoxinA Near the End of Treatment Cycle for Chronic Migraine: A 4-Year Clinical Experience.

Headache 2020 Feb 22;60(2):430-440. Epub 2019 Nov 22.

McCasland Family Comprehensive Headache Center, Ochsner Neuroscience Institute, Ochsner Clinic Foundation, New Orleans, LA, USA.

Introduction: The injection interval for onabotulinumtoxinA (BoNTA) in the management of chronic migraine (CM) is 12 weeks (78-84 days). The aim of this study was to review patient-reported wearing off effect (WOE) of the therapeutic benefit of BoNTA near the end of the treatment cycle. We intended to describe the demographics of patients at baseline and compare groups of patients with multiple episodes of WOE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/head.13713DOI Listing
February 2020

A Randomized, Double-Blind, Controlled Trial Shows that Onabotulinum Toxin A Nerve Blocks do Not Provide Improved Pain Control in Men with Chronic Scrotal Pain.

J Urol 2020 04 18;203(4):767-772. Epub 2019 Oct 18.

Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada.

Purpose: The use of onabotulinum toxin A to chemically denervate the testis has been studied as a minimally invasive therapy to treat chronic scrotal pain. To our knowledge no randomized, controlled trials of onabotulinum toxin A for chronic scrotal pain management have been reported to date.

Materials And Methods: In this double-blind, randomized, controlled trial men with chronic scrotal pain who achieved at least temporary pain relief following a cord block with local anesthesia were randomly assigned to a block using local anesthesia alone vs local anesthesia plus 200 IU onabotulinum toxin A. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000658DOI Listing

Progressive Cervical Spondylotic Myelopathy Caused by Tic Disorders in a Young Adult with Tourette Syndrome.

Korean J Neurotrauma 2019 Oct 18;15(2):199-203. Epub 2019 Sep 18.

Department of Neurosurgery, Gyeongsang National University School of Medicine, Jinju, Korea.

Involuntary movement of the cervical spine can cause damage to the cervical spinal cord. Cervical myelopathy may occur at an early age in involuntary movement disorders, such as tics. We report the case of a 21-year-old man with Tourette syndrome, who developed progressive quadriparesis, which was more severe in the upper extremities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.13004/kjnt.2019.15.e24DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826097PMC
October 2019

Botulinum toxin injection for internal anal sphincter achalasia after pull-through surgery in Hirschsprung disease.

Medicine (Baltimore) 2019 Nov;98(45):e17855

Department of Pediatric Surgery, Seoul National University College of Medicine, Seoul, Korea.

Botulinum toxin (Botox) was introduced for the management of internal anal sphincter (IAS) achalasia after a pull-through procedure in Hirschsprung disease (HD). We conducted a prospective evaluation of the efficacy and safety of this Botox treatment.Our study group included 15 patients with HD (median age, 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000017855DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855586PMC
November 2019

Botulinum toxin injections to cranial sutures for chronic migraine Rewinding the technique using ultrasound imaging.

Toxicon 2019 Oct 23;172:19-22. Epub 2019 Oct 23.

Hacettepe University Medical School, Department of Physical and Rehabilitation Medicine, Ankara, Turkey.

The treatment of chronic migraine headache is quite challenging and new alternatives are still being explored for its management. Onabotulinum toxin A (BoNT-A) applied into extracranial muscles has been shown to inhibit the release of acetylcholine and local nociceptive peptides at the sensory nerve endings. As the highest concentration of extracranial pain fibers are located at/nearby the sutures, extracranial applications of BoTN-A are suggested to be performed to sutures rather than into the head and neck muscles in the treatment of chronic migraine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.toxicon.2019.10.239DOI Listing
October 2019

Osteoarthritis of the hip conservative treatment with type A botulinum toxin.

Gac Med Mex 2019 ;155(Suppl 1):S44-S48

Department of Physical Medicine and Rehabilitation; City of Mexico, Mexico.

Introduction: Osteoarthritis (OA) of the hip is a low-grade inflammatory disease of multiple etiology that has a limited conservative management and insufficiently explored. The application of botulinum toxin type A (BoNT-A) produces in the applied muscle a temporary, delimitable and reversible flaccid paralysis, which applied in a strategic way achieves to reduce mechanical stress and pain.

Objective: To evaluate the effect on pain perception, functionality and rigidity and changes in flexibility, internal and external rotation, before and 90 days after the application of BoNT-A. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/GMM.M19000289DOI Listing
March 2020
1 Read

Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome.

Cochrane Database Syst Rev 2019 Oct 6;10:CD012552. Epub 2019 Oct 6.

Argentine Cochrane Centre, Instituto Universitario Hospital Italiano, Potosí 4234, Buenos Aires, Buenos Aires, Argentina, C1199ACL.

Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common disorder in which the two main clinical features are pelvic pain and lower urinary tract symptoms. There are currently many approaches for its management, using both pharmacological and non-pharmacological interventions. The National Institute of Health - Chronic Prostatitis Symptom Index (NIH-CPSI) score is a validated measure commonly used to measure CP/CPPS symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD012552.pub2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778620PMC
October 2019
5 Reads

Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?

Toxins (Basel) 2019 09 19;11(9). Epub 2019 Sep 19.

College of Medicine, Fu-Jen Catholic University, New Taipei City 24205, Taiwan.

Patients with benign prostatic hyperplasia (BPH) can exhibit various lower urinary tract symptoms (LUTS) owing to bladder outlet obstruction (BOO), prostatic inflammation, and bladder response to BOO. The pathogenesis of BPH involves an imbalance of internal hormones and chronic prostatic inflammation, possibly triggered by prostatic infection, autoimmune responses, neurogenic inflammation, oxidative stress, and autonomic dysfunction. Botulinum toxin A (BoNT-A) is well recognized for its ability to block acetylcholine release at the neuromuscular junction by cleaving synaptosomal-associated proteins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/toxins11090547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784075PMC
September 2019
3 Reads
2.480 Impact Factor

The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials.

Brain Behav 2019 10 21;9(10):e01409. Epub 2019 Sep 21.

Department of Neurology, The Second People's Hospital of Huai'an, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China.

Background: Although recent studies have shown that botulinum toxin-A (BTX-A) has a good analgesic effect on trigeminal neuralgia (TN) and peripheral neuropathic pain (PNP), the quality of evidence is low due to limited data. This meta-analysis is used to synthesize existing evidence for the treatment of these conditions with BTX-A.

Methods: Relevant trials were accessed by using an electronic search in databases (Web of Science, PubMed, EMBASE, Cochrane Library, and ClinicalTrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/brb3.1409DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790324PMC
October 2019
4 Reads

Anesthesia for Patients Undergoing Peroral Endoscopic Myotomy Procedures: A Review of the Literature.

Anesth Analg 2020 05;130(5):1331-1340

Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine.

Idiopathic achalasia is a motility disorder of the esophagus with important implications on anesthesia and periprocedural management. As new and more complex treatment options develop, anesthesiologists are increasingly involved with these patients. The cardinal symptoms of achalasia are as follows: dysphagia, regurgitation, chest pain, and weight loss. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1213/ANE.0000000000004420DOI Listing
May 2020
3 Reads

Ligand-dependent spatiotemporal signaling profiles of the μ-opioid receptor are controlled by distinct protein-interaction networks.

J Biol Chem 2019 11 12;294(44):16198-16213. Epub 2019 Sep 12.

Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia

Ligand-dependent differences in the regulation and internalization of the μ-opioid receptor (MOR) have been linked to the severity of adverse effects that limit opiate use in pain management. MOR activation by morphine or [d-Ala,-MePhe, Gly-ol]enkephalin (DAMGO) causes differences in spatiotemporal signaling dependent on MOR distribution at the plasma membrane. Morphine stimulation of MOR activates a Gα-Gβγ-protein kinase C (PKC) α phosphorylation pathway that limits MOR distribution and is associated with a sustained increase in cytosolic extracellular signal-regulated kinase (ERK) activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.RA119.008685DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827304PMC
November 2019
2 Reads

Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series.

Clin Rheumatol 2019 Dec 3;38(12):3669-3676. Epub 2019 Sep 3.

Charles Wolfson Center for Reconstructive Surgery, Royal Free Hospital, London, UK.

Introduction: Raynaud's phenomenon (RP) is a common condition and causes pain, paraesthesia, ulceration and gangrene. Botulinum toxin A (Btx-A) is effective when injected via a digital palmar approach, in the treatment of severe RP. However, hand weakness resulting from lumbrical malfunction is a recognized complication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-019-04762-4DOI Listing
December 2019
2 Reads
1.774 Impact Factor

Current and emerging evidence-based treatment options in chronic migraine: a narrative review.

J Headache Pain 2019 Aug 30;20(1):92. Epub 2019 Aug 30.

Headache Center Department of Medical, Surgical, Neurological, Metabolic, and Aging Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.

Background: Chronic migraine is a disabling condition that is currently underdiagnosed and undertreated. In this narrative review, we discuss the future of chronic migraine management in relation to recent progress in evidence-based pharmacological treatment.

Findings: Patients with chronic migraine require prophylactic therapy to reduce the frequency of migraine attacks, but the only currently available evidence-based prophylactic treatment options for chronic migraine are topiramate and onabotulinumtoxinA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s10194-019-1038-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734211PMC
August 2019
4 Reads

Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines.

Toxins (Basel) 2019 08 8;11(8). Epub 2019 Aug 8.

Department of Fundamental Disciplines and Clinical Prevention, Faculty of Medicine, Transilvania University of Brasov, 500019 Brasov, Romania.

Background: In 1989, Botulinum toxin (BoNT) was accepted by the FDA for the management of some ophthalmic disorders. Although it was initially considered a lethal toxin, in recent times, Botulinum toxin A (BoNT-A), which is the more used serotype, has expanded to cover different clinical conditions, primarily characterized by neuropathic pain, including migraines and headaches. Evidence suggests that migraines are influenced by hormonal factors, particularly by estrogen levels, but very few studies have investigated the prevalence and management strategies for migraines according to the hormonal status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/toxins11080465DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722780PMC
August 2019
1 Read

Anal fissure: diagnosis, management, and referral in primary care.

Br J Gen Pract 2019 Aug;69(685):409-410

Colorectal Surgery, NHS Lothian, Edinburgh.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3399/bjgp19X704957DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650108PMC
August 2019
9 Reads

Dual Actions of Ketorolac in Metastatic Ovarian Cancer.

Cancers (Basel) 2019 Jul 24;11(8). Epub 2019 Jul 24.

Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.

Cytoreductive surgery and chemotherapy are cornerstones of ovarian cancer treatment, yet disease recurrence remains a significant clinical issue. Surgery can release cancer cells into the circulation, suppress anti-tumor immunity, and induce inflammatory responses that support the growth of residual disease. Intervention within the peri-operative window is an under-explored opportunity to mitigate these consequences of surgery and influence the course of metastatic disease to improve patient outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11081049DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721416PMC
July 2019
3 Reads

Botulinum toxin type A applications for masticatory myofascial pain and trigeminal neuralgia: what is the evidence regarding adverse effects?

Clin Oral Investig 2019 Sep 24;23(9):3411-3421. Epub 2019 Jul 24.

Bauru Orofacial Pain Group, Department of Prosthodontics, Bauru School of Dentistry, University of Sao Paulo, Bauru, SP, Brazil.

Objectives: The objective of the study was to conduct a systematic review of literature assessing botulinum toxin type A (BoNT-A) safety and adverse effects in the treatment of myofascial pain (MFP) and trigeminal neuralgia (TN).

Materials And Methods: The search for articles by two specific researchers involved the PubMed, EMBASE, Web of Science, and Scopus databases. Specific terms were used, and no publication time and language restrictions were applied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00784-019-03026-4DOI Listing
September 2019
5 Reads

Subcutaneous Injection of Botulinum Toxin in Patients with Post Herpetic Neuralgia. A Preliminary Study.

J Assoc Physicians India 2018 Jul;66(7):48-49

Neuro physician and Director (M & HS) JLNH and RC, Bhilai, Chattisgarh;Corresponding Author.

Background: Post Herpetic neuralgia (PHN) is neuropathic pain that occurs after herpes zoster infection. Several treatments have been suggested in the management of PHN. This study evaluates the efficacy of subcutaneous injection of botulinum toxin in patients suffering from PHN. Read More

View Article

Download full-text PDF

Source
July 2018
5 Reads

Comparison of the Efficacies of Dry Needling and Botox Methods in the Treatment of Myofascial Pain Syndrome Affecting the Temporomandibular Joint.

J Craniofac Surg 2019 Jul;30(5):1556-1559

Department of Otorhinolaryngology, University of Health Sciences, Adana City Hospital, Aydin, Turkey.

Background: To compare the efficacies of botulinum toxin-A injection and dry needling methods in the treatment of patients with myofascial pain syndrome (MPS) in the temporomandibular joint (TMJ).

Methods: In this prospective study, 40 MPS patients (29 women, 11 men) were randomly assigned to abobotulinum toxin-A injection (Group 1, n = 20) or dry needling (Group 2, n = 20) groups. Pain, crepitation, functional limitation, maximum mouth opening, jaw strength were evaluated at baseline and 6 weeks, and the results in both groups were compared. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SCS.0000000000005473DOI Listing
July 2019
1 Read

The Interdisciplinary Management of Foot Drop.

Dtsch Arztebl Int 2019 May;116(20):347-354

Clinic for Neurosurgery, University Medical Center Knappschaftskrankenhaus Bochum, Bochum, Germany; Department of Surgery, Plastic Surgery and Hand Surgery, Pauwelsklinik Aachen, Aachen, Germany; Department of Neurology, University Hospital Münster, Münster, Germany; Department of Orthopedic and Trauma Surgery, University Medical Center Knappschaftskrankenhaus Bochum, Bochum, Germany.

Background: Foot drop can be caused by a variety of diseases and injuries. Although it is a common condition, its overall incidence has not been reported to date. Foot drop markedly restricts the everyday activities of persons suffering from it. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3238/arztebl.2019.0347DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637663PMC
May 2019
3 Reads

Emerging Novel Pharmacological Non-opioid Therapies in Headache Management: a Comprehensive Review.

Curr Pain Headache Rep 2019 Jul 8;23(8):53. Epub 2019 Jul 8.

Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Medical School, Brigham and Women's Hospital, 75 Francis St, Boston, MA, 02115, USA.

Purpose Of Review: Chronic headache is a significant worldwide problem despite advances in treatment options. Chronic headaches can have significant a detrimental impact on the activities of daily living.

Recent Findings: Patients who do not obtain relief from chronic head and neck pain from conservative treatments are commonly being managed with interventional treatments. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11916-019-0808-7
Publisher Site
http://dx.doi.org/10.1007/s11916-019-0808-7DOI Listing
July 2019
6 Reads